Entry |
|
Name |
EML4-ALK fusion kinase to RAS-ERK signaling pathway
|
Definition |
EML4-ALK -> RAS -> RAF -> MEK -> ERK -> CCND1 |
Expanded |
(238v1,238v2) -> (3265,3845,4893) -> (369,673,5894) -> (5604,5605) -> (5594,5595) -> 595 |
Class |
|
Type |
Variant
|
Pathway |
|
Disease |
H00014 | Non-small cell lung cancer |
|
Gene |
238 | ALK; ALK receptor tyrosine kinase |
3265 | HRAS; HRas proto-oncogene, GTPase |
3845 | KRAS; KRAS proto-oncogene, GTPase |
4893 | NRAS; NRAS proto-oncogene, GTPase |
369 | ARAF; A-Raf proto-oncogene, serine/threonine kinase |
673 | BRAF; B-Raf proto-oncogene, serine/threonine kinase |
5894 | RAF1; Raf-1 proto-oncogene, serine/threonine kinase |
5604 | MAP2K1; mitogen-activated protein kinase kinase 1 |
5605 | MAP2K2; mitogen-activated protein kinase kinase 2 |
5594 | MAPK1; mitogen-activated protein kinase 1 |
5595 | MAPK3; mitogen-activated protein kinase 3 |
|
Variant |
238v1 (EML4-ALK) EML4-ALK fusion
238v2 (EML4-ALK) First generation TKI-resistant ALK1 mutation
|
Reference |
|
Authors |
Reungwetwattana T, Weroha SJ, Molina JR |
Title |
Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC). |
Journal |
|
Reference |
|
Authors |
Roskoski R Jr |
Title |
Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition. |
Journal |
|
Reference |
|
Authors |
Janne PA, Gray N, Settleman J |
Title |
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. |
Journal |
|
Reference |
|
Authors |
Solomon B, Wilner KD, Shaw AT |
Title |
Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer. |
Journal |
|
LinkDB |
|